# Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

> **NCT05051722** · — · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 3110 (estimated)

## Conditions studied

- Endometrial Cancer
- Cervical Cancer
- Atypical Endometrial Hyperplasia
- Cervical Dysplasia
- Adnexal Mass
- Ovarian Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Vaginal Fluid Collection
- **DIAGNOSTIC_TEST:** Blood Collection

## Key facts

- **NCT ID:** NCT05051722
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-03
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 3110 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05051722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05051722, "Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05051722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*